Bayer – An International, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures. BAY 59-7939/17454

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/161/1/16